Scienmag

APRIL 10, 2021

[link] Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes Credit: MD Anderson Cancer Center HOUSTON – Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and […].

Gene 97

Gene Protein Research Genetics 97

The Pharma Data

APRIL 10, 2021

Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience. Company thanks Director Robert W. Pangia as he retires from the Boardg. today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company’s board of directors at its 2021 annual meeting of stockholders, scheduled for June 2, 2021.

Development 52

Development Life Science Drugs Research 52

Scienmag

APRIL 10, 2021

[link] Tumor profiling has opposite effect among more socially advantaged populations Credit: Joshua Clark/UIC Active surveillance leads to improved quality of life Men with low health literacy seven times less likely to accept active surveillance Prostate cancer and active surveillance patient education is needed Tumor gene profiling is a tool that can help patients with […].

Gene 94

Gene Medicine 94

BioTech 365

APRIL 10, 2021

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer Greenwich LifeSciences Presents Immune Response Phase IIb Poster, … Continue reading →

Immune Response 52

Immune Response 52

Advertisement

Clinical Supply

Scienmag

APRIL 10, 2021

[link] Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumor microenvironment (TME) Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study, published today in Cancer Immunology Research, a journal of the […].

Research 75

Research Medicine 75

BioTech 365

APRIL 10, 2021

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021 PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual … Continue reading →

Production 40

Production Research 40

Scienmag

APRIL 10, 2021

[link] Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors Credit: Dana-Farber Cancer Institute Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy – an abnormal number of chromosomes – tend to respond better to immune checkpoint inhibitor […].

Research 52

Research Clinical Trials Clinical Trials Allergies 52

BioTech 365

APRIL 10, 2021

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021 C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, … Continue reading →

40

40

Scienmag

APRIL 10, 2021

[link] UCLA clinical trial shows bispecific CAR T cells targeting CD19/CD20 are safe and effective in patients with relapsed or refractory B-cell lymphoma LOS ANGELES — Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack […].

Clinical Trials 46

Clinical Trials Clinical Trials Trials Research 46

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

BioTech 365

APRIL 10, 2021

F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and Activation CAMBRIDGE, United Kingdom … Continue reading →

Antibody 40

Antibody 40

Drug Patent Watch

APRIL 10, 2021

This chart shows the pharmaceutical companies with the most pellets dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most pellets dosed drugs…. The post Which pharmaceutical companies have the most pellets dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs 52

BioTech 365

APRIL 10, 2021

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types … Continue reading →

In-Vivo 40

In-Vivo 40

BioTech 365

APRIL 10, 2021

Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR) Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the … Continue reading →

Antibody 52

Antibody Research 52

Advertisement

Clinical Supply

BioTech 365

APRIL 10, 2021

Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin’s Lymphoma Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin’s Lymphoma In the Phase III … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers … Continue reading →

52

52

BioTech 365

APRIL 10, 2021

Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 Ultimovacs Presents the INITIUM Study Design as a Trial-in-Progress Poster at AACR Annual Meeting 2021 OSLO, Norway–(BUSINESS WIRE)–$ULTI #AACR2021—Ultimovacs ASA (“Ultimovacs”, ticker ULTI), announced that … Continue reading →

Trials 52

Trials 52

BioTech 365

APRIL 10, 2021

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting – Preclinical research included in poster supports clinical … Continue reading →

Trials 40

Trials Research 40

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

BioTech 365

APRIL 10, 2021

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model Study demonstrates GMI-1757’s impact … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers Preliminary data demonstrate a robust increase … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021 Arch Oncology Presents New Preclinical T-ALL Data on Highly-differentiated Anti-CD47 Antibody AO-176 at AACR 2021 — Late-breaking presentation highlights preclinical data for AO-176 in T-ALL … Continue reading →

Antibody 40

Antibody 40

BioTech 365

APRIL 10, 2021

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting CAMBRIDGE, Mass.

40

40

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

BioTech 365

APRIL 10, 2021

New Clinical Responses for AGEN1181 Presented at AACR New Clinical Responses for AGEN1181 Presented at AACR 7 objective responses observed to date in multiple tumor types New responses reported in patients with melanoma and ovarian cancer Benefit seen in patients … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting … Continue reading →

40

40

BioTech 365

APRIL 10, 2021

Valneva Files Registration Statement for Proposed United States Initial Public Offering Valneva Files Registration Statement for Proposed United States Initial Public Offering Saint-Herblain (France), April 10, 2021 – Valneva SE (the “Company”), a specialty vaccine company focused on the development … Continue reading →

Vaccination 40

Vaccination Vaccine Development 40

BioTech 365

APRIL 10, 2021

Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates Saint-Herblain (France), April 10, 2021 – Valneva SE (“Valneva” or the “Company”), a specialty vaccine company … Continue reading →

Vaccination 40

Vaccination Vaccine 40

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials